Skip to main content

Scienture Holdings, Inc.

corporate_fare Company Profile

Scienture Holdings, Inc.

SCNX·NASDAQ·Life Sciences·CIK 0001382574

Scienture Holdings, Inc. is a pharmaceutical company that develops and sells products for central nervous system and cardiovascular diseases in the United States. The company is developing SCN-102, an oral liquid formulation of losartan potassium, which is currently in Phase 1 trials. SCN-102 is intended to treat hypertension, diabetic nephropathy, and reduce the risk of stroke in patients with hypertension and left ventricular hypertrophy. Scienture Holdings also develops SCN-104, a multi-dose dihydroergotamine mesylate (DHE) injection pen. Additionally, the company is working on SCN-106, a thrombolytic agent designed to bind to fibrin in clots and convert entrapped plasminogen to plasmin. Another product in development is SCN-107, a long-acting injection suspension formulation of a non-opioid analgesic for postsurgical local and regional pain relief. Scienture Holdings, Inc. is headquartered in Commack, New York.

Scienture Holdings, Inc. (NASDAQ:SCNX) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 28 items for SCNX at importance 7 or higher on its 1–10 market-impact scale.

Recent high-impact activity:

  • Scienture Secures Third Patent for ARBLI™ Oral Suspension, Extending Market Exclusivity to 2041
  • Scienture Holdings Files Investor Presentation with Material Discrepancy Regarding Recent Debt Financing
  • Secures $11M in Highly Restrictive Debt Financing with Extensive Collateral and Punitive Default Terms
  • Amended 10-K Reveals Widespread Insider Trading Reporting Failures Among Executives and Directors
  • Nasdaq Grants Scienture 180-Day Extension to Regain Bid Price Compliance

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$431.61K
Net Income
-$41.51M
Diluted EPS
-$2.70
Op. Cash Flow
-$13.38M
Gross Profit
$331.48K
Operating Income
-$42.59M
Cash & Equivalents
$6.66M
Debt / Equity
0.00×
Net Margin
-96.18×
Shares Outstanding
40.63M sh
Source: 10-K · filed 2026-04-30 · accession 0001493152-26-020707
$2.46 +1.03% today
52-week range · as of 2026-11-19 $2.24 – $18.75
Market cap
$4.07M
Volume
29.9K (0.6× avg)
3-mo avg 46.5K
Live data · 2026-11-22 03:53 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed SCNX - Filings & News (Page 2)

SCNX
May 06, 2026, 8:05 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $0.4069
Real-time Price: $2.46 info
Change: Reverse Stock Split info
Market Cap: $4.073M info
SCNX
May 05, 2026, 5:00 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $0.3906
Real-time Price: $2.46 info
Change: Reverse Stock Split info
Market Cap: $4.073M info
SCNX
May 01, 2026, 5:25 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $0.4012
Real-time Price: $2.46 info
Change: Reverse Stock Split info
Market Cap: $4.073M info
SCNX
Apr 30, 2026, 5:00 PM EDT
Filing Type: 10-K/A
Importance Score:
7
Price at Filing: $0.400
Real-time Price: $2.46 info
Change: Reverse Stock Split info
Market Cap: $4.073M info
SCNX
Apr 15, 2026, 8:05 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $0.340
Real-time Price: $2.46 info
Change: Reverse Stock Split info
Market Cap: $4.073M info
SCNX
Mar 30, 2026, 8:09 AM EDT
Source: Dow Jones Newswires
Importance Score:
9
Price at Filing: $0.4191
Real-time Price: $2.46 info
Change: Reverse Stock Split info
Market Cap: $4.073M info
SCNX
Mar 30, 2026, 8:05 AM EDT
Filing Type: 10-K
Importance Score:
9
Price at Filing: $0.420
Real-time Price: $2.46 info
Change: Reverse Stock Split info
Market Cap: $4.073M info
SCNX
Mar 11, 2026, 8:05 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $0.484
Real-time Price: $2.46 info
Change: Reverse Stock Split info
Market Cap: $4.073M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets